A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer
Status:
Active, not recruiting
Trial end date:
2021-08-29
Target enrollment:
Participant gender:
Summary
The purpose the study is to measure the effect of nivolumab (BMS-936558) in reducing tumor
size in subjects with metastatic or unresectable bladder cancer.